Skip to main content
UNC Lineberger

Pancreatic Cancer

Tumor-intrinsic and Cancer-associated Fibroblast Subtypes Independently Predict Outcomes in Pancreatic Cancer Ann Surg. 2024 Jun 18. doi: 10.1097/SLA.0000000000006416. Online ahead of print.

  • Lee JJ, Kearney JF, Trembath HE, Hariharan A, LaBella ME, Kharitonova EV, Chan PS, Morrison AB, Cliff A, Meyers MO, Kim HJ, Rashid NU, Peng XL, Yeh JJ.

Determination of permissive and restraining cancer-associated fibroblast (DeCAF) subtypes bioRxiv [Preprint]. 2024 May 17:2024.05.14.594197. doi: 10.1101/2024.05.14.594197.

  • Peng XL, Kharitonova EV, Xu Y, Kearney JF, Luan C, Chan PS, Hariharan A, McCabe IC, Leary JR, Morrison AB, Trembath HE, LaBella ME, Herera Loeza SG, Cliff A, Kim HJ, Belt BA, Panni RZ, Linehan DC, Damrauer JS, Iuga AC, Kim WY, Rashid NU, Yeh JJ.

First-in-Class Humanized Antibody against Alternatively Spliced Tissue Factor Augments Anti-Metastatic Efficacy of Chemotherapy in a Preclinical Model of Pancreatic Ductal Adenocarcinoma.  Int J Mol Sci. 2024 Feb 23;25(5):2580. doi: 10.3390/ijms25052580.

  • Lewis CS, Backman C, Ahsan S, Cliff A, Hariharan A, Yeh JJ, Zhang X, Xie C, Sohal DPS, Bogdanov VY.
Myofibroblastic cancer-associated fibroblast subtype heterogeneity in pancreatic cancer.  J Surg Oncol. 2024 Jan 17. doi: 10.1002/jso.27582.
  • Kearney JF, Trembath HE, Chan PS, Morrison AB, Xu Y, Luan CF, McCabe IC, Zarmer SA, Kim HJ, Peng XL, Yeh JJ.

Identifying patient profiles of disparate care in resectable pancreas cancer using latent class analysis. J Surg Oncol. 2023 Aug;128(2):254-261. doi: 10.1002/jso.27275. Epub 2023 Apr 24.

  • Maduekwe UN, Stephenson BJK, Yeh JJ, Troester MA, Sanoff HK.

Open-source curation of a pancreatic ductal adenocarcinoma gene expression analysis platform (pdacR) supports a two-subtype model. Commun Biol. 2023 Feb 10;6(1):163. doi: 10.1038/s42003-023-04461-6.

  • Torre-Healy LA, Kawalerski RR, Oh K, Chrastecka L, Peng XL, Aguirre AJ, Rashid NU, Yeh JJ, Moffitt RA.

Balance between immunoregulatory B cells and plasma cells drives pancreatic tumor immunity. Cell Rep Med. 2022 Sep 20;3(9):100744. doi: 10.1016/j.xcrm.2022.100744. Epub 2022 Sep 12.

  • Mirlekar B, Wang Y, Li S, Zhou M, Entwistle S, De Buysscher T, Morrison A, Herrera G, Harris C, Vincent BG, Ting JP, Rashid N, Kim WY, Yeh JJ, Pylayeva-Gupta Y.

Truncated O-Glycan-Bearing MUC16 Enhances Pancreatic Cancer Cells Aggressiveness via α4β1 Integrin Complexes and FAK Signaling. Int J Mol Sci. 2022 May 13;23(10):5459. doi: 10.3390/ijms23105459.

  • Rajesh C, Sagar S, Rathinavel AK, Chemparathy DT, Peng XL, Yeh JJ, Hollingsworth MA, Radhakrishnan P.

The Q61H mutation decouples KRAS from upstream regulation and renders cancer cells resistant to SHP2 inhibitors. Nat Commun. 2021 Nov 1;12(1):6274. doi: 10.1038/s41467-021-26526-y.

  • Gebregiworgis T, Kano Y, St-Germain J, Radulovich N, Udaskin ML, Mentes A, Huang R, Poon BPK, He W, Valencia-Sama I, Robinson CM, Huestis M, Miao J, Yeh JJ, Zhang ZY, Irwin MS, Lee JE, Tsao MS, Raught B, Marshall CB, Ohh M, Ikura M.

The PDAC Extracellular Matrix: A Review of the ECM Protein Composition, Tumor Cell Interaction, and Therapeutic Strategies. Front Oncol. 2021 Oct 6;11:751311. doi: 10.3389/fonc.2021.751311. eCollection 2021.

  • Perez VM, Kearney JF, Yeh JJ.

High-Dimensional Precision Medicine From Patient-Derived Xenografts. J Am Stat Assoc. 2021;116(535):1140-1154. doi: 10.1080/01621459.2020.1828091. Epub 2020 Nov 12.

  • Rashid NU, Luckett DJ, Chen J, Lawson MT, Wang L, Zhang Y, Laber EB, Liu Y, Yeh JJ, Zeng D, Kosorok MR.

Pathology and Molecular Characteristics of Pancreatic Cancer. Surg Oncol Clin N Am. 2021 Oct;30(4):609-619. doi: 10.1016/j.soc.2021.06.003. Epub 2021 Jul 22.

  • Kearney JF, Adsay V, Yeh JJ.

GM-CSF drives myelopoiesis, recruitment and polarisation of tumour-associated macrophages in cholangiocarcinoma and systemic blockade facilitates antitumour immunity. Gut. 2022 Jul;71(7):1386-1398. doi: 10.1136/gutjnl-2021-324109. Epub 2021 Aug 19.

  • Ruffolo LI, Jackson KM, Kuhlers PC, Dale BS, Figueroa Guilliani NM, Ullman NA, Burchard PR, Qin SS, Juviler PG, Keilson JM, Morrison AB, Georger M, Jewell R, Calvi LM, Nywening TM, O’Dell MR, Hezel AF, De Las Casas L, Lesinski GB, Yeh JJ, Hernandez-Alejandro R, Belt BA, Linehan DC.

Single-cell transcriptome analysis defines heterogeneity of the murine pancreatic ductal tree. Elife. 2021 May 19;10:e67776. doi: 10.7554/eLife.67776.

  • Hendley AM, Rao AA, Leonhardt L, Ashe S, Smith JA, Giacometti S, Peng XL, Jiang H, Berrios DI, Pawlak M, Li LY, Lee J, Collisson EA, Anderson MS, Fragiadakis GK, Yeh JJ, Ye CJ, Kim GE, Weaver VM, Hebrok M.

Gene Targeting in Disease Networks. Front Genet. 2021 Apr 23;12:649942. doi: 10.3389/fgene.2021.649942. eCollection 2021.

  • Weighill D, Ben Guebila M, Glass K, Platig J, Yeh JJ, Quackenbush J.

Isoforms of MUC16 activate oncogenic signaling through EGF receptors to enhance the progression of pancreatic cancer. Mol Ther. 2021 Apr 7;29(4):1557-1571. doi: 10.1016/j.ymthe.2020.12.029. Epub 2020 Dec 25.

  • Thomas D, Sagar S, Liu X, Lee HR, Grunkemeyer JA, Grandgenett PM, Caffrey T, O’Connell KA, Swanson B, Marcos-Silva L, Steentoft C, Wandall HH, Maurer HC, Peng XL, Yeh JJ, Qiu F, Yu F, Madiyalakan R, Olive KP, Mandel U, Clausen H, Hollingsworth MA, Radhakrishnan P.

Pancreatic ductal adenocarcinoma progression is restrained by stromal matrix. J Clin Invest. 2020 Sep 1;130(9):4704-4709. doi: 10.1172/JCI136760.

  • McGregor K, Pishvaian MJ, Blais EM, Lu B, Li M, Hollingsworth M, Stashko C, Volmar K, Yeh JJ, Weaver VM, Wang ZJ, Tempero MA, Weichert W, Collisson EA.

Enhanced Efficacy of Combination of Gemcitabine and Phosphatidylserine-Targeted Nanovesicles against Pancreatic Cancer. Mol Ther. 2020 Aug 5;28(8):1876-1886. doi: 10.1016/j.ymthe.2020.05.013. Epub 2020 Jun 8.

  • N’Guessan KF, Davis HW, Chu Z, Vallabhapurapu SD, Lewis CS, Franco RS, Olowokure O, Ahmad SA, Yeh JJ, Bogdanov VY, Qi X.

Virtual microdissection identifies distinct tumor- and stroma-specific subtypes of pancreatic ductal adenocarcinoma. Nat Genet. 2015 Oct;47(10):1168-78. doi: 10.1038/ng.3398. Epub 2015 Sep 7. PMID: 26343385; PMCID: PMC4912058.

  • Moffitt RA, Marayati R, Flate EL, Volmar KE, Loeza SG, Hoadley KA, Rashid NU, Williams LA, Eaton SC, Chung AH, Smyla JK, Anderson JM, Kim HJ, Bentrem DJ, Talamonti MS, Iacobuzio-Donahue CA, Hollingsworth MA, Yeh JJ. 

Irreversible JNK1-JUN inhibition by JNK-IN-8 sensitizes pancreatic cancer to 5-FU/FOLFOX chemotherapy. JCI Insight. 2020 Apr 23;5(8). pii: 129905. doi: 10.1172/jci.insight.129905.

    • Lipner MB, Peng XL, Jin C, Xu Y, Gao Y, East MP, Rashid NU, Moffitt RA, Herrera Loeza SG, Morrison AB, Golitz BT, Vaziri C, Graves LM, Johnson GL, Yeh JJ.

B cell-Derived IL35 Drives STAT3-Dependent CD8+ T-cell Exclusion in Pancreatic Cancer. Cancer Immunol Res. 2020 Mar;8(3):292-308. doi: 10.1158/2326-6066.CIR-19-0349. Epub 2020 Feb 5.

  • Mirlekar B, Michaud D, Lee SJ, Kren NP, Harris C, Greene K, Goldman EC, Gupta GP, Fields RC, Hawkins WG, DeNardo DG, Rashid NU, Yeh JJ, McRee AJ, Vincent BG, Vignali DAA, Pylayeva-Gupta Y.

Modeling Between-Study Heterogeneity for Improved Replicability in Gene Signature Selection and Clinical Prediction. Journal of the American Statistical Association. Forthcoming; NIHMSID: NIHMS1540952.

  • Rashid NU, Li Q, Yeh J, Ibrahim JG.

Purity independent subtyping of tumors (PurIST), a clinically robust single sample classifier for tumor subtyping in pancreatic cancer. Clin Cancer Res.  2020 Jan 1;26(1):82-92. doi: 10.1158/1078-0432.CCR-19-1467. Epub 2019 Nov 21.

  • Rashid NU, Peng XL, Jin C, Moffitt RA, Volmar KE, Kawalerski R, Belt BA, Panni RZ, Nywening TM, Herrera SG, Moore KJ, Hennessey S, Morrison AB, Nayyar A, Change AE, Schmidt B, Kim HJ, Linehan DC, Yeh JJ.

De novo compartment deconvolution and weight estimation of tumor samples using DECODER. Nature Commun. 2019 Oct 18, in press.

  • Peng XL, Moffitt RA, Torphy RJ, Volmar KE, Yeh JJ.

Antitumor Responses in the Absence of Toxicity in Solid Tumors by Targeting B7-H3 via Chimeric Antigen Receptor T Cells. Cancer Cell. 2019 Feb 11;35(2):221-237.. NIHMS1035462

  • Du H, Hirabayashi K, Ahn S, Kren NP, Montgomery SA, Wang X, Tiruthani K, Mirlekar R, Michaud D, Greene K, Herrera SG, Xu Y, Sun C, Chen Y, Ma X, Ferrone CR, Pylayeva-Gupta Y, Yeh JJ, Liu R, Savoldo B, Ferrone S, Dotti G.

Tyrosyl phosphorylation of KRAS stalls GTPase cycle via alteration of switch I and switch II conformation. Nat Commun. 2019 Jan 15;10(1):224.

  • Kano Y, Gebregiworgis T, Marshall CB, Radulovich N, Poon BPK, St-Germain J, Cook JD, Valencia-Sama I, Grant BMM, Herrera SG, Miao J, Raught B, Irwin MS, Lee JE, Yeh JJ, Zhang ZY, Tsao MS, Ikura M, Ohh M.

The vitamin D receptor gene as a determinant of survival in pancreatic cancer patients: Genomic analysis and experimental validation. PLoS One. 2018 Aug 14;13(8):30202272.

  • Innocenti F, Owzar K, Jiang C, Etheridge AS, Gordân R, Sibley AB, Mulkey F, Niedzwiecki D, Glubb D, Neel N, Talamonti MS, Bentrem DJ, Seiser E, Yeh JJ, Van Loon K, McLeod H, Ratain MJ, Kindler HL, Venook AP, Nakamura Y, Kubo M, Petersen GM, Bamlet WR, McWilliams RR.

Impact of neoadjuvant therapy on postoperative outcomes after pancreaticoduodenectomy. J Surg Oncol. 2018 Sep:188(3):455-462.

  • Cools KS, Sanoff HK, Kim HJ, Yeh JJ, Stitzenberg KB.

Altered exocrine function can drive adipose wasting in early pancreatic cancer. Nature. 2018 Jun. 558(7711):600-604.

  • Danai LV, Babic A, Rosenthal MH, Dennstedt EA, Muir A, Lien EC, Mayers JR, Tai K, Lau AN, Jones-Sali P, Prado CM, Petersen GM, Takahashi N, Sugimoto M, Yeh JJ, Lopez N, Bardeesy N, Fernandez-Del Castillo C, Liss AS, Koong AC, Bui J, Yuan C, Welch MW, Brais LK, KulkeMH, Dennis C, Clish CB, Wolpin BM, Vander Heiden MG.

Real-time genomic characterization of advanced pancreatic cancer to enable precision medicine. Cancer Discovery. 2019 Jun 14. Pii:CD-18-9275. Epub ahead of print.

  • Aguirre AJ, Nowak JA, Camarda ND, Moffitt RA, Ghazani AA, Hazar-Rethinam M, Raghavan S,Kim J, Brais LK, Ragon D, Welch MW, Reilly E, McCabe D, Marini L, Anderka K, Helvie K, Oliver N, Babic A, Da Silva A, Nadres B, Van Seventer EE, Shahzade HA, St Pierre JP, Burke KP, Clancy TE, Cleary JM, Doyle LA, Jajoo K, McCleary NJ, Meyerhardt JA, Murphy JE, Ng K, Patel AK, Perez K, Rosenthal MH, Rubinson DA, Ryou M, Shpairo GI, Sicinska E, Silverman SG, Nagy RJ, Lanman RB, Knoerzer D, Welsch DJ, Yurgelun MB, Fuchs CS, Garraway LA, Getz G, Hornick JL, Johnson BE, Kulke MH, Mayer RJ, Miller JW, Shyn PB, Tuveson DA, Wagle N, Yeh JJ, Hahn WC, Corcoran RB, Yeh JJ, Carter SL, Wolpin BM.

Application of integrated drug screening/kinome analysis to identify inhibitors of gemcitabine-resistant pancreatic cancer cell growth. SLAS Discovery. 2018 May 1:2472555218773045. Epub ahead of print.

  • Krulikas LJ, McDonald IM, Lee B, Okumu DO, East MP, Gilbert TSK, Herring LE, Golitz BT, Wells CI, Axtman AD, Zuercher WJ, Willson TM, Kireev D, Yeh JJ, Johnson GL, Baines AT, Graves LM.

Impact of formulation on iontophoretic delivery of the FOLFIRINOX regimen for the treatment of pancreatic cancer. Cancer Chemotherapy Pharmacology. 2018 Jun;81(6):991-998.

  • Byrne JD, Jajja MRN, O’Neill AT, Schorzman AN, Keller AW, Luft JC, Zamboni WC, DeSimone JM, Yeh JJ.

Stromal Content Is Correlated With Tissue Site, Contrast Retention, and Survival in Pancreatic Adenocarcinoma. JCO Precision Oncology. 2018 Jan 16.

  • Torphy RJ, Wang Z, True-Yasaki A, Volmar KE, Rashid N, Yeh B, Johansen JS, Hollingsworth MA, Yeh JJ, Collisson EA.

Genomics-Driven Precision Medicine for Advanced Pancreatic Cancer – Early Results from the COMPASS Trial. Clinical Cancer Research. 2017 Dec 29. Epub ahead of print.

  • Aung KL, Fischer SE, Denroche RE, Jang GH, Dodd A, Creighton S, Southwood B, Liang SB, Chadwick D, Zhang A, O’Kane GM, Albaba HAA, Moura S, Grant RC, Miller JK, Mbabaali F, Pasternack D, Lungu IM, Bartlett JMS, Ghai S, Lemire M, Holter S, Connor AA, Moffitt RA, Yeh JJ, Timms L, Krzyzanowski PM, Dhani NC, Hedley DW, Notta F, Wilson JM, Moore MJ, Gallinger S, Knox JJ.

Integrated Genomic Characterization of Pancreatic Ductal Adenocarcinoma. Cancer Cell. 2017 Aug 14;32(2):185-203.e13. doi: 10.1016/j.ccell.2017.07.007.

  •  Cancer Genome Atlas Research Network (Yeh JJ)

Dual selection with discrete microfluidics for isolation of orthogonal subpopulations of circulating tumor cells. Nature Partner Journal Precision Oncology. 2017 Jul 25.

  • Witek MA, Auffort RD, Wang H, Kamande JW, Jackson JM, Pullagurla SW, Hupert ML, Usary J, Wysham WZ, Hilliard D, Montgomery S, Bae-Jump V, Carey LA, GehrigPA, Milowsky MI, Perou CM, Soper JT, Whang YE, Yeh JJ*, Martin G*, Soper SA*.
  • *co-corresponding

Genetic and pharmacological inhibition of TTK impairs pancreatic cancer cell line growth by inducing lethal chromosomal instability. PLoS One. 2017 Apr 5; 12(4):e0174863.

  • Stratford JK, Yan F, Hill RA, Major MB, Graves LM, Der CJ, Yeh JJ.

Selective single cell isolation for genomics using microraft arrays. Nucleic Acids Research. 2016 44(17):8292.

  • Welch JD, Williams LA, DiSalvo M, Brandt AT, Marayati R, Sims CE, Allbritton NL, Prins JF, Yeh JJ*, Jones CD*.
  • *co-corresponding

Hexokinase 2 promotes tumor growth and metastasis by regulating lactate production. Oncotarget. 2016 Jun 1;8(34):56081-56094.

  • Anderson M, Marayati R, Moffitt RA, Yeh JJ.

Iontophoretic device delivery for the localized treatment of pancreatic ductal adenocarcinoma. Proc Natl Acad Sci USA. 2016 Feb 8. pii: 201600421

  • Byrne JD, Jajja MR, O’Neill AT, Schorzman AN, Keeler AW, Luft JC, Zamboni WC, DeSimone J*, Yeh JJ*.
  • *co-corresponding

Metformin treatment does not inhibit growth of pancreatic cancer patient-derived xenografts. PLoS One. 2016 Jan 13;11(1):e0147113.

  • Lipner MB, Marayati R, Deng Y, Wang X, Raftery L, O’Neil BH, Yeh JJ.

Long-term ERK inhibition in KRAS-mutant pancreatic cancer is associated with MYC degradation and senescence-like growth suppression. Cancer Cell. 2016 Jan; 29:1-15.

  • Hayes TK, Neel NF, Hu C, Gautam P, Chenard M, Long B, Aziz M, Kassner M, Bryant KL, Pierobon M, Marayati R, Kher S, George SD, Petricoin III, EF, Yin HH, Nelkin B, Cox AD, Yeh JJ, Der CJ.

Virtual microdissection of pancreatic ductal adenocarcinoma reveals tumor and stroma subtypes. Nature Genetics. 2015 Oct;47(10):1168-78

  • Moffitt RA, Marayati R, Volmar KE, Hoadley, KA, Anderson J, Bentrem DJ, Talamonti MS, Iacobuzio-Donahue CA, Hollingsworth MA, Yeh JJ.

Local Iontophoretic Administration of Cytotoxic Therapies to Solid Tumors. Sci Transl Med. 2015 Feb 4;7(273):273ra14

  • Byrne JD, Jajja MR, O’Neill AT, Bickford LR, Keller AW, Hyder N, Wagner K, Deal AM, Little RE, Moffit RM, Stack C, Nelson M, Brooks CR, Lee W, Luft JC, Napier ME, Darr D, Anders CK, Stack RS, Tepper J, Wang AZ, Zamboni WC, Yeh JJ*, DeSimone J*.
  • *co-corresponding

KRAS and PIK3CA mutation frequencies in patient derived xenograft (PDX) models of pancreatic and colorectal cancer are reflective of patient tumors and stable across passages. American Surgeon. 2014 Sep;80(9):873-7.

  • Tignanelli CJ, Herrera Loeza SG, Yeh JJ.

Small sample sorting of primary adherent cells by automated micropallet imaging and release. Cytometry A. 2014 Jul;85(7):642-9.

  • Shah PK, Herrera-Loeza SG, Sims CE, Yeh JJ, Allbritton NL.

Measurement of Protein Kinase B Activity in Single Primary Human Pancreatic Cancer Cells. Analytical Chemistry. 2014 May 6; 86(9):4573-80.

  • Proctor A, Herrera-Loeza SG, Wang Q, Lawrence D, Yeh JJ, Allbritton, NL.

Circulating Tumor Cells as a Biomarker of Response to Treatment in Patient-Derived Xenograft Mouse Models of Pancreatic Adenocarcinoma. PLoS One. 2014 Feb 19; 9)2:389474.

  • Torphy RJ, Tigananelli CJ, Kamande JW, Moffitt RA, Herrera Loeza SG, Soper SA, Yeh JJ.

Micropallet arrays for the capture, isolation and culture of circulating tumor cells from whole blood of mice engrafted with primary human pancreatic adenocarcinoma. Biosensors and Bioelectronics. 2014 Apr 15;54:476-83.

  • Gach PC, Attayek PJ, Whittlesey RL, Yeh JJ, Allbritton NL.

Response to MLN8237 in pancreatic cancer is not dependent on RalA phosphorylation. Molecular Cancer Therapy. 2014 Jan;13(1):122-33.

  • Neel NF, Stratford JK, Shinde V, Ecsedy JA, Martin TD, Der CJ, Yeh JJ.

UV activation of polymeric high aspect ratiomicrostructures: ramifications in antibody surface loading for circulating tumor cell selection. Lab Chip. 2014 Jan 7;14(1):106-17.

  • Jackson JM, Witek MA, Hupert ML, Brady C, Pullagurla S, Kamande J, Aufforth RD, Tignanelli CJ, Torphy RJ, Yeh JJ, Soper SA.

Isolation and in vitro culture of rare cancer stem cells from patient-derived xenografts of pancreatic ductal adenocarcinoma. Analytical Chemistry. 2013 Aug 6;85(15):7271-8.

  • Gach PC, Attayek PJ, Herrera G, Yeh JJ, Allbritton NL.

GSK-3α promotes oncogenic KRAS function in pancreatic cancer via TAK1-TAB stabilization and regulation of non-canonical NF-κB. Cancer Discov. 2013 Jun 3(6):690-703.

  • Bang D, Wilson W, Ryan M, Yeh JJ, Baldwin AS.

Tumor-derived tissue factor activates coagulation and enhances thrombosis in a mouse xenograft model of human pancreatic cancer. Blood. 2012 Jun 119(23):5543-52.

  • Wang JG, Geddings JE, Aleman MM, Cardenas JC, Chantrathammachart P, Williams JC, Kirchhofer D, Bogdanov VY, Bach RR, Rak J, Church FC, Wolberg AS, Pawlinski R, Key NS, Yeh JJ, Mackman N.

Differential expression of metabolic genes in tumor and stromal components of primary and metastatic loci in pancreatic adenocarcinoma. PLoS One. 2012 Mar;7(3):e32996.

  • Chaika NV, Yu F, Purohit V, Mehla K, Lazenby AJ, DiMaio D, Anderson JM, Yeh JJ, Johnson KR, Hollingsworth MA, Singh PK.

The RalB small GTPase mediates formation of invadopodia through a GTPase-activating protein-independent function of the RalBP1/RLIP76 effector. Molecular Cell Biology. 2012 Apr; 32(8):1374-86.

  • Neel NF, Rossman KL, Martin TD, Hayes TK, Yeh JJ, Der CJ.

The oncogenic kinase Pim-1 is modulated by K-Ras signaling and mediates transformed growth and radioresistance in human pancreatic ductal adenocarcinoma cells. Carcinogenesis. 2011 Apr;32(4):488-95.

  • Xu D, Allsop SA, Witherspoon SM, Snider JL, Yeh JJ, Fiordalisi JJ, White CD, Williams D, Cox AD, Baines AT.

A six-gene signature predicts survival of patients with localized pancreatic ductal adenocarcinoma. PLoS Med. 2010 Jul 13;7(7):e1000307. doi: 10.1371/journal.pmed.1000307. PMID: 20644708

  • Stratford JK, Bentrem DJ, Anderson JM, Fan C, Volmar KA, Marron JS, Routh ED, Caskey LS, Samuel JC, Der CJ, Thorne LB, Calvo BF, Kim HJ, Talamonti MS, Iacobuzio-Donahue CA, Hollingsworth MA, Perou CM, Yeh JJ.

Isoform-specific upregualtion of palladin in human and murine pancreas tumors. PLoS One. 2010 April 26;5(4):e10347.

  • Goicoechea SM, Bednarski B, Stack C, Cowan DW, Volmar K, Thorne L, Cukierman E, Rustgi AK, Brentnall T, Hwang RF, McCulloch CA, Yeh JJ, Bentrem DJ, Hochwald S, Hingorani SR, Kim HJ, Otey CA.